| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 9.58 Billion | USD 17.82 Billion | 6.40% | 2024 |
FrequentlyAsked Questions
Liver cancer diagnostics refers to the wide range of tests and procedures conducted to diagnose the presence of liver cancer cells.
The global liver cancer diagnostics market is expected to be driven by the growing prevalence of the disease across the globe.
According to study, the global liver cancer diagnostics market size was worth around USD 9.58 billion in 2024 and is predicted to grow to around USD 17.82 billion by 2034.
The CAGR value of the liver cancer diagnostics market is expected to be around 6.40% during 2025-2034.
The global liver cancer diagnostics market will be led by North America during the forecast period
The global liver cancer diagnostics market is led by players like Becton, Dickinson & Company, Abbott Laboratories, Siemens Healthineers, Koninklijke Philips N.V. (Philips), Bio‑Rad Laboratories, Inc., F. Hoffmann‑La Roche Ltd. (Roche), Illumina, Inc., FUJIFILM (including FUJIFILM Wako Diagnostics / Medical Systems), NeoGenomics Laboratories, Inc., Epigenomics AG, Guardant Health, Thermo Fisher Scientific, Inc., Sysmex Corporation, Qiagen N.V., and bioMérieux SA.
The report explores crucial aspects of the liver cancer diagnostics market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients